Literature DB >> 25682445

Sclerotherapy with bleomycin versus surgical excision for extracervical cystic lymphatic malformations in children.

Burak Ardıçlı1, İbrahim Karnak2, Arbay Ö Çiftçi1, F Cahit Tanyel1, M Emin Şenocak1.   

Abstract

PURPOSE: Sclerotherapy (ST) with bleomycin is an effective treatment for cervical cystic lymphatic malformations (LM) in children. However, its efficacy for treating extracervical cystic LM in children has not been investigated adequately. This retrospective study compares the efficacy of ST with surgery for treating extracervical cystic LM in children.
METHODS: The subjects of this study were children treated for extracervical cystic LM at our hospital between 1970 and 2013. We evaluated retrospectively the hospital records of these children for age, gender, presenting symptoms, location of the lesion, radiological findings, treatments, complications, duration of hospitalization, and outcome.
RESULTS: We analyzed the records of 70 children (M:F = 1:9) with a mean age of 52.57 ± 54.87 months (range 1-204 months). The number of children treated by surgery alone, ST alone, and surgery plus ST was 53 (77 %), 13 (18 %), and 4 (5 %), respectively. Surgery comprised total excision (n = 41), near-total excision (n = 9), partial excision (n = 6), and incisional biopsy (n = 1). The complication and recurrence rates were lower, the complete response rate was higher, and the length of hospitalization was shorter in the ST group than in the surgery group (5 vs. 15 % and 8 vs. 17 %, respectively, p < 0.05; 91 vs. 77 %, respectively, p = 0.05; and 2.42 ± 1.67 vs. 13.57 ± 16.24 days, respectively, p = 0.03).
CONCLUSION: ST is as safe as surgery for extracervical macrocystic or mixed LMs in children, but is much more effective with higher success rates and lower recurrence rates. Thus, ST provides a cost-effective and appropriate mode of treatment for children with extracervical cystic LM.

Entities:  

Keywords:  Bleomycin; Child; Cystic lymphatic malformation; Lymphangioma; Sclerotherapy

Year:  2015        PMID: 25682445     DOI: 10.1007/s00595-015-1128-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  16 in total

1.  Lymphatic malformations: a proposed management algorithm.

Authors:  J C Oosthuizen; P Burns; J D Russell
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-02-18       Impact factor: 1.675

2.  Extensive cervical-mediastinal cystic lymphatic malformation treated with sclerotherapy in a child with Klippel-Trenaunay syndrome.

Authors:  Levent Duman; Ibrahim Karnak; Devrim Akinci; F Cahit Tanyel
Journal:  J Pediatr Surg       Date:  2006-01       Impact factor: 2.545

3.  Abdominal lymphangiomas in children: interest of the laparoscopic approach.

Authors:  P de Lagausie; A Bonnard; D Berrebi; O Lepretre; L Statopoulos; A Delarue; J-M Guys
Journal:  Surg Endosc       Date:  2006-12-20       Impact factor: 4.584

4.  Percutaneous drainage and ablation as first line therapy for macrocystic and microcystic orbital lymphatic malformations.

Authors:  Robert H Hill; William E Shiels; Jill A Foster; Craig N Czyz; Andrew Stacey; Kelly R Everman; Kenneth V Cahill
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2012 Mar-Apr       Impact factor: 1.746

5.  Cystic retroperitoneal lymphangioma: treatment by image-guided percutaneous catheter drainage and sclerotherapy.

Authors:  K R Shankar; C J Roche; H M Carty; R R Turnock
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

6.  Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient-evaluated improvement.

Authors:  Ahmad I Alomari; Victoria E Karian; David J Lord; Horacio M Padua; Patricia E Burrows
Journal:  J Vasc Interv Radiol       Date:  2006-10       Impact factor: 3.464

7.  Huge intra- and extrathoracic lymphangioma in a baby successfully treated by sclerotherapy with OK-432.

Authors:  P Degenhardt; B Dieckow; H Mau
Journal:  Eur J Pediatr Surg       Date:  2006-06       Impact factor: 2.191

8.  Cystic hygroma of unusual sites: report of two cases.

Authors:  Bilal Mirza; Lubna Ijaz; Shahid Iqbal; Ghulam Mustafa; Muhammad Saleem; Afzal Sheikh
Journal:  Afr J Paediatr Surg       Date:  2011 Jan-Apr

9.  Sclerotherapy with bleomycin does not adversely affect facial nerve function in children with cervicofacial cystic lymphatic malformation.

Authors:  Afra Karavelioğlu; Cağri Mesut Temuçin; F Cahit Tanyel; Arbay O Ciftci; Mehmet Emin Senocak; Ibrahim Karnak
Journal:  J Pediatr Surg       Date:  2010-08       Impact factor: 2.545

10.  New operative strategy for refractory microcystic lymphangioma.

Authors:  Shigeru Ono; Yuki Tsuji; Katsuhisa Baba; Yoshiko Usui; Satohiko Yanagisawa; Kosaku Maeda
Journal:  Surg Today       Date:  2013-11-30       Impact factor: 2.549

View more
  5 in total

1.  Cervical lymphangioma in adults: A report of seven cases and review of the literature.

Authors:  Jianwei Wang; Yujuan Yang; Jing Guo; Yao Yao; Luchao Dong; Yakui Mou; Yu Zhang; Xicheng Song
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-04-22

2.  Bleomycin Sclerotherapy in Massive Macrocystic Lymphatic Malformation: Minimal Complications with Maximum Results.

Authors:  Ankur Bhatnagar; Zafar Neyaz; Brajesh Singh; Ashwani Mishra; Vijai Datta Upadyayaya; Basant Kumar
Journal:  J Cutan Aesthet Surg       Date:  2020 Oct-Dec

3.  Results of Injection Sclerotherapy with Bleomycin in Pediatric Lymphatic Malformations.

Authors:  Vipan Kumar; Subhasis Roy Choudhury; Partap Singh Yadav; Vikram Khanna; Amit Gupta; Rajiv Chadha; Rama Anand
Journal:  J Indian Assoc Pediatr Surg       Date:  2021-07-12

Review 4.  Recent Progress in Lymphangioma.

Authors:  Xiaowei Liu; Cheng Cheng; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  Front Pediatr       Date:  2021-12-15       Impact factor: 3.418

5.  Lymphatic malformations in children: treatment outcomes of sclerotherapy in a large cohort.

Authors:  Frédérique C M Bouwman; Silje S Kooijman; Bas H Verhoeven; Leo J Schultze Kool; Carine J M van der Vleuten; Sanne M B I Botden; Ivo de Blaauw
Journal:  Eur J Pediatr       Date:  2020-10-13       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.